BGB-16673の研究は、ブルートンチロシンキナーゼ(BTK)とB細胞白血病/リンパ腫2タンパク質(BCL2)阻害剤の両方に以前にさらされた慢性リンパ球性白血病の参加者の調査員の選択と比較した研究 (CaDAnCe-302)
調査官の選択(イデラリシブとリツキシマブまたはベンデキシンまたはベネトカラックスとリツキシマブの退却)と比較して、BGB-16673の第3相、非盲検、ランダム化研究は、以前はBCL2およびBCL2イノベーションの両方にさらされていた慢性リンパ球性白血病患者の患者においてリツキシラブの退却)と比較しています。
The purpose of this study is to investigate the efficacy and safety of tacabrutideg compared with investigator's choice (idelalisib plus rituximab [for CLL only] or bendamustine plus rituximab or venetoclax plus rituximab retreatment) in participants with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) previously exposed to both BTK inhibitors (BTKi) and BCL2 inhibitors (BCL2i).
調査の概要
状態
詳細な説明
CLL (chronic lymphocytic leukemia) and SLL (small lymphocytic lymphoma) are slow-growing blood cancers that affect the same type of white blood cell (called B lymphocytes). They are considered different forms of the same disease. CLL mainly occurs in the blood and bone marrow, while SLL mainly affects the lymph nodes.
Tacabrutideg is a type of medicine called a BTK degrader. BTK (Bruton's tyrosine kinase) is a protein that helps cancer cells survive. Tacabrutideg is designed to attach to the BTK protein and tag it for removal, so that the body's own cellular "clean-up" system breaks it down and clears it away. When more BTK is removed from the body, it interferes with the signals needed for the cancer cells to multiply and survive and may also help overcome resistance caused by certain changes in BTK.
The purpose of this study is to test if tacabrutideg is safe and if it works in adults with CLL or SLL. The main goal of the study is to find the amount of time participants live without their disease getting worse after starting the study treatment.
This study has two treatment groups. Participants will be randomly assigned by chance, to one of the treatment groups. Participants and the study doctors will know what treatment is received during the study.
The study will enroll approximately 250 adults at multiple centers worldwide with CLL or SLL. The overall time to participate in this study is 36 months. Participants will make regular visits to the clinic for treatment, health checks, blood tests, and tumor and imaging tests.
Our company, previously known as BeiGene, is now officially BeOne Medicines. Because some of our older studies were sponsored under the name BeiGene, you may see both names used for this study on this website.
研究の種類
入学 (推定)
段階
- フェーズ 3
連絡先と場所
研究連絡先
- 名前:Study Director
- 電話番号:1.877.828.5568
- メール:clinicaltrials@beonemed.com
研究場所
-
-
Arkansas
-
Jonesboro、Arkansas、アメリカ、72401
- 募集
- St Bernards Medical Center
-
-
California
-
Los Angeles、California、アメリカ、90095-3075
- 募集
- UCLA Department of Medicine Hematologyoncology
-
San Diego、California、アメリカ、92103-2106
- 募集
- Scripps Prebys Cancer Center
-
Whittier、California、アメリカ、90602
- 募集
- Pih Health Whittier Hospital
-
-
Colorado
-
Aurora、Colorado、アメリカ、80012-5405
- 募集
- Rocky Mountain Cancer Centers (Williams) Usor
-
Golden、Colorado、アメリカ、80401
- 募集
- Intermountain Health Lutheran Hospital Cancer Center of Colorado
-
-
Florida
-
Fort Myers、Florida、アメリカ、33912
- 募集
- Florida Oncology and Hematology
-
Jacksonville、Florida、アメリカ、32207-8432
- 募集
- Baptist Md Anderson Cancer Center
-
Weston、Florida、アメリカ、33331-3609
- 募集
- Cleveland Clinic Florida
-
-
Georgia
-
Atlanta、Georgia、アメリカ、30322-1013
- 募集
- Emory University Winship Cancer Institute
-
Atlanta、Georgia、アメリカ、30342
- 募集
- Northside Cancer Center
-
-
Louisiana
-
Baton Rouge、Louisiana、アメリカ、70808-4365
- 募集
- Our Lady of the Lake Hospital
-
-
Maryland
-
Bethesda、Maryland、アメリカ、20817-7847
- 募集
- American Oncology Partners of Maryland Pa
-
-
Michigan
-
Grand Rapids、Michigan、アメリカ、49503-2560
- 募集
- Corewell Health the Michigan Cancer Consortium
-
-
Minnesota
-
Minneapolis、Minnesota、アメリカ、55455-0341
- 募集
- University of Minnesota
-
-
Missouri
-
Chesterfield、Missouri、アメリカ、63017
- 募集
- St Lukes Center For Cancer Care
-
Springfield、Missouri、アメリカ、65807-5288
- 募集
- Oncology Hematology Associates
-
-
Montana
-
Billings、Montana、アメリカ、59102-6746
- 募集
- St Vincent Frontier Cancer Center
-
-
Nebraska
-
Omaha、Nebraska、アメリカ、68130-2042
- 募集
- Oncology Hematology West, Pc Dba Nebraska Cancer Specialists
-
-
New York
-
New York、New York、アメリカ、10065-6800
- 募集
- Memorial Sloan Kettering Cancer Center Mskcc
-
Shirley、New York、アメリカ、11967
- 募集
- New York Cancer and Blood Specialists
-
Syracuse、New York、アメリカ、13210-2306
- 募集
- Suny Upstate Medical University
-
Westbury、New York、アメリカ、11590-5119
- 募集
- Optum Medical Care, Pc
-
-
Ohio
-
Cleveland、Ohio、アメリカ、44106-1716
- 募集
- University Hospitals
-
Dayton、Ohio、アメリカ、45415
- 募集
- Dayton Physician Network
-
-
Oregon
-
Eugene、Oregon、アメリカ、97401
- 募集
- Oncology Associates of Oregon Willamette Valley Cancer Center
-
-
Pennsylvania
-
Pittsburgh、Pennsylvania、アメリカ、15224
- 募集
- West Penn Hospital
-
York、Pennsylvania、アメリカ、17403-5049
- 募集
- Cancer Care Associates of York
-
-
Texas
-
Temple、Texas、アメリカ、76508-0001
- 募集
- Baylor Scott and White Health Medical Center Temple
-
Tyler、Texas、アメリカ、75702-7522
- 募集
- Texas Oncology Tyler
-
-
-
-
-
Caba、アルゼンチン、CP1114
- 募集
- FUNDALEU
-
Caba、アルゼンチン、C1431
- 募集
- CEMIC
-
Caba、アルゼンチン、1425
- 募集
- Hospital Aleman
-
Ciudad Autonoma Buenos Aires、アルゼンチン、1413
- 募集
- Hospital Italiano de Buenos Aires
-
Ciudad Autonoma Buenos Aires、アルゼンチン、1426
- 募集
- Instituto Alexander Fleming (Iaf)
-
San Miguel de Tucumán、アルゼンチン、4000
- 募集
- Cice 9 de Julio Sanatorio 9 de Julio
-
-
-
-
-
Aberdeen、イギリス、AB25 2ZN
- 募集
- Aberdeen Royal Infirmary
-
Birmingham、イギリス、B9 5SS
- 募集
- Birmingham Heartlands Hospital
-
Bournemouth、イギリス、BH7 7DW
- 募集
- The Royal Bournemouth and Christchurch Hospitals Nhs Foundation
-
London、イギリス、SW3 6JJ
- 募集
- Royal Marsden Hospital
-
London、イギリス、NW1 2PG
- 募集
- University College Hospital
-
Southampton、イギリス、SO16 6YD
- 募集
- Southampton General Hospital
-
-
-
-
-
Bari、イタリア、70124
- 募集
- Irccs Istituto Tumori Giovanni Paolo Ii
-
Florence、イタリア、50134
- 募集
- Aou Careggi, Servizio Sanitario Toscana
-
Milan、イタリア、20132
- 募集
- Ospedale San Raffaele
-
Milan、イタリア、20122
- 募集
- Fondazione Irccs Ca Granda Ospedale Maggiore Policlinico
-
Naples、イタリア、80131
- 募集
- Azienda Ospedaliera Universitaria Federico Ii
-
Novara、イタリア、28100
- 募集
- Aou Maggiore Della Carita
-
Pavia、イタリア、27100
- 募集
- Irccs Policlinico San Matteo, Universita Degli Studi Di Pavi
-
Perugia、イタリア、6129
- 募集
- Ospedale Santa Maria Della Misericordia
-
Roma、イタリア、00168
- 募集
- Fondazione Policlinico Universitario Agostino Gemelli
-
-
-
-
-
Amsterdam、オランダ、1081 HV
- 募集
- Amsterdam Umc Vu Mc
-
-
-
-
New South Wales
-
Concord、New South Wales、オーストラリア、NSW 2139
- 募集
- Concord Repatriation General Hospital
-
Gosford、New South Wales、オーストラリア、NSW 2250
- 募集
- Gosford Hospital
-
Port Macquarie、New South Wales、オーストラリア、NSW 2444
- 募集
- Port Macquarie Base Hospital
-
Randwick、New South Wales、オーストラリア、NSW 2031
- 募集
- Prince of Wales Hospital
-
-
Queensland
-
Toowoomba、Queensland、オーストラリア、QLD 4350
- 募集
- Toowoomba Hospital
-
-
South Australia
-
Bedford PK、South Australia、オーストラリア、SA 5042
- 募集
- Flinders Medical Centre
-
-
Victoria
-
Melbourne、Victoria、オーストラリア、VIC 3004
- 募集
- The Alfred Hospital
-
-
Western Australia
-
West Perth、Western Australia、オーストラリア、WA 6005
- 募集
- Perth Blood Institute
-
-
-
-
Ontario
-
Hamilton、Ontario、カナダ、L8V 5C2
- 募集
- Juravinski Cancer Centre
-
London、Ontario、カナダ、N6A 5W9
- 募集
- London Health Sciences Centre
-
Ottawa、Ontario、カナダ、K1H 8L6
- 募集
- The Ottawa Hospital Cancer Centre
-
-
Quebec
-
Greenfield Park、Quebec、カナダ、J4V 2H1
- 募集
- Centre Integre de Sante Et de Services Sociaux de La Monteregie Centre
-
Montreal、Quebec、カナダ、QC H3t 1E2
- 募集
- Jewish General Hospital
-
SaintJerome、Quebec、カナダ、J7Z 5T3
- 募集
- Unite de Recherche Clinique Du Cisss Des Laurentides
-
-
-
-
-
Brno、チェコ、625 00
- 募集
- Fakultni Nemocnice Brno
-
Hradec Králové、チェコ、500 03
- 募集
- Fakultni Nemocnice Hradec Kralove
-
Ostrava、チェコ、708 00
- 募集
- Fakultni Nemocnice Ostrava
-
Prague、チェコ、10000
- 募集
- Vseobecna Fakultni Nemocnice V Praze
-
-
-
-
-
Ankara、トルコ(Türkiye)、6500
- 募集
- Gazi University
-
Ankara、トルコ(Türkiye)、06200
- 募集
- Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital
-
Balçova、トルコ(Türkiye)、35330
- 募集
- Dokuz Eylul University
-
Dokuma、トルコ(Türkiye)、07025
- 募集
- Antalya Memorial Hospital
-
Sakarya、トルコ(Türkiye)、54100
- 募集
- Sakarya Training and Research Hospital
-
-
-
-
-
Augsburg、ドイツ、86156
- 募集
- Universitatsklinikum Augsburg
-
Berlin、ドイツ、10715
- 募集
- Praxis Am Volkspark
-
Chemnitz、ドイツ、09116
- 募集
- Klinikum Chemnitz Ggmbh
-
Essen、ドイツ、45122
- 募集
- Universitatsklinikum Essen (Aor)
-
Frankfurt am Main、ドイツ、60389
- 募集
- Centrum Fur Haematologie Und Onkologie Bethanien
-
Freiburg im Breisgau、ドイツ、79106
- 募集
- Universitatsklinikum Freiburg I Br Klinik Fur Innere Medizin I
-
Hamburg、ドイツ、20251
- 募集
- Universitatsklinikum Hamburg Eppendorf
-
Heidelberg、ドイツ、69120
- 募集
- Universitatsklinikum Heidelberg
-
Homburg、ドイツ、66421
- 募集
- Universitatsklinikum Des Saarlandes
-
Koblenz、ドイツ、56068
- 募集
- Invo Institut Fur Versorgungsforschung in Der Onkologie
-
Leipzig、ドイツ、04103
- 募集
- Universitaetsklinikum Leipzig Aor
-
Münster、ドイツ、48149
- 募集
- Universitatsklinikum Munster Medizinische Klinik A
-
-
-
-
-
Belo Horizonte、ブラジル、30110-022
- 募集
- CETUS
-
Brasília、ブラジル、70200-730
- 募集
- Hospital Sirio Libanes Brasilia
-
Curitiba、ブラジル、81520-060
- 募集
- Hospital Erasto Gaertner
-
Florianópolis、ブラジル、88020-210
- 募集
- Centro de Ensino E Pesquisa Em Oncologia de Santa Catarina (Cepen)
-
Joinville、ブラジル、89201-260
- 募集
- Instituto Joinvilense de Hematologia E Oncologia
-
Niterói、ブラジル、24020-096
- 募集
- Complexo Hospitalar de Niteroi
-
Novo Hamburgo、ブラジル、93510-223
- 募集
- Vida Hematologia
-
Porto Alegre、ブラジル、90110-270
- 募集
- Centro Gaucho Integrado de Oncologia Hospital Mae de Deus
-
Rio de Janeiro、ブラジル、22250-040
- 募集
- Oncoclinicas Rio de Janeiro Sa
-
Rio de Janeiro、ブラジル、22061-080
- 募集
- Hospital Sao Lucas Dasa Oncologia
-
Salvador、ブラジル、41253-190
- 募集
- Hospital Sao Rafael (Rede Dor)
-
São Paulo、ブラジル、05652-900
- 募集
- Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein
-
São Paulo、ブラジル、04014-002
- 募集
- Instituto Brasileiro de Controle Do Cancer
-
São Paulo、ブラジル、01401-004
- 募集
- Instituto Dor de Pesquisa E Ensino Sao Paulo
-
Vitória、ブラジル、29043-260
- 募集
- Hospital Santa Rita de Cassia Afecc
-
-
-
-
-
Brzozów、ポーランド、36-200
- 募集
- Szpital Specjalist W Brzozowie,Podkarpacki Osrodek Onkologiczny
-
Katowice、ポーランド、40-519
- 募集
- Pratia Onkologia Katowice
-
Krakow、ポーランド、30-727
- 募集
- Pratia McM Krakow
-
Lodz、ポーランド、93-510
- 募集
- Wojewodzkie Wielospecjalistyczne Centrum Onkologii I Traumatologii Im M Kopernika W Lodzi
-
Lublin、ポーランド、20-090
- 募集
- Uniwersytecki Szpital Kliniczny Nr 4 W Lublinie
-
Wroclaw、ポーランド、50-367
- 募集
- Uniwersytecki Szpital Kliniczny Im Jana Mikulicza Radeckiego We Wroclawiu
-
-
-
-
-
Kumamoto、日本、860-8556
- 募集
- Kumamoto University Hospital
-
Okayama、日本、701-1192
- 募集
- National Hospital Organization Okayama Medical Center
-
Osaka、日本、545-8586
- 募集
- Osaka Metropolitan University Hospital
-
-
Aichi-ken
-
Nagoya、Aichi-ken、日本、464-8681
- 募集
- Aichi Cancer Center Hospital Clinical Oncology
-
-
Chiba
-
Chiba、Chiba、日本、260-8717
- 募集
- Chiba Cancer Center
-
-
Ehime
-
Matsuyama、Ehime、日本、791-0280
- 募集
- Nho Shikoku Cancer Center
-
-
Hiroshima
-
Hiroshima、Hiroshima、日本、730-8619
- 募集
- Hiroshima Red Cross Hospital and Atomic Bomb Survivors Hospital
-
-
Hokkaido
-
Sapporo、Hokkaido、日本、064-0804
- 募集
- Aiiku Hospital
-
-
Hyōgo
-
AmagasakiCity、Hyōgo、日本、660-8550
- 募集
- Hyogo Prefectural Amagasaki General Medical Center
-
-
Kagoshima-ken
-
Kagoshima、Kagoshima-ken、日本、890-8520
- 募集
- Kagoshima University Hospital
-
-
Kyoto
-
KyotoShi、Kyoto、日本、602-8566
- 募集
- University Hospital, Kyoto Prefectural Univ of Medicine
-
-
Miyagi
-
Sendai、Miyagi、日本、980-8574
- 募集
- Tohoku University Hospital
-
-
Niigata
-
Niigata、Niigata、日本、951-8520
- 募集
- Niigata University Medical and Dental Hospital
-
-
Okayama-ken
-
Kurashikishi、Okayama-ken、日本、710-8602
- 募集
- Kurashiki Central Hospital
-
-
Osaka
-
Hirakata、Osaka、日本、573-1191
- 募集
- Kansai Medical University Hospital
-
Sakai、Osaka、日本、590-0197
- 募集
- Kindai University Hospital
-
-
Saitama
-
Kawagoeshi、Saitama、日本、350-8550
- 募集
- Saitama Medical Center
-
-
Tokyo
-
Bunkyoku、Tokyo、日本、113-8677
- 募集
- Tokyo Metropolitan Komagome Hospital
-
Shinagawaku、Tokyo、日本、141-0022
- 募集
- Ntt Medical Center Tokyo
-
-
-
-
Busan Gwang'yeogsi
-
Seogu、Busan Gwang'yeogsi、韓国、49201
- 募集
- Dong A University Hospital
-
-
Daegu Gwang'yeogsi
-
Junggu、Daegu Gwang'yeogsi、韓国、41944
- 募集
- Kyungpook National University Hospital
-
-
Gyeonggi-do
-
IlsandongGu GoyangSi、Gyeonggi-do、韓国、10408
- 募集
- National Cancer Center (Korea)
-
-
Jeonnam-Gwangju S.M. City
-
HwasunGun、Jeonnam-Gwangju S.M. City、韓国、58128
- 募集
- Chonnam National University Hwasun Hospital
-
-
Seoul Teugbyeolsi
-
GangnamGu、Seoul Teugbyeolsi、韓国、06351
- 募集
- Samsung Medical Center
-
SeochoGu、Seoul Teugbyeolsi、韓国、06591
- 募集
- The Catholic University of Korea, Seoul St Marys Hospital
-
Seoul、Seoul Teugbyeolsi、韓国、03080
- 募集
- Seoul National University Hospital
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Confirmed diagnosis of CLL or SLL, requiring treatment, based on 2018 international workshop on chronic lymphocytic leukemia (iwCLL) criteria.
- Previously received treatment for CLL/SLL with both a BTKi and a BCL2i.
- Participants with SLL must have measurable disease by computer tomography (CT)/magnetic resonance imaging (MRI).
- Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2.
- Adequate liver function.
- Adequate blood clotting function.
Exclusion Criteria:
- Known prolymphocytic leukemia (defined per iwCLL 2018 as prolymphocytes comprising >55% of peripheral blood lymphocytes), or currently suspected or history of Richter's transformation within the last 5 years.
- Prior autologous stem cell transplant or chimeric antigen receptor-T cell therapy in the last 6 months.
- Known central nervous system involvement.
- Prior exposure to any BTK protein degraders.
- Active fungal, bacterial and/or viral infection requiring parenteral systemic therapy.
- Clinically significant cardiovascular disease.
- Prior invasive fungal infection, except if patient agrees to receive secondary antifungal prophylaxis during the entire treatment period.
- Known contraindications to azole antifungal agents, including hypersensitivity reactions.
- Receiving systemic immunosuppressive therapy for a nonmalignant condition within 28 days before the first dose of study treatment.
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Arm A: Tacabrutideg monotherapy
Participants will receive tacabrutideg once daily until any of the treatment discontinuation criteria are met |
Administered orally
他の名前:
|
|
アクティブコンパレータ:Arm B: Investigator's Choice
Participants will receive investigator's choice of idelalisib plus rituximab for CLL only or bendamustine plus rituximab, or venetoclax plus rituximab retreatment. |
Administered orally Administered intravenously Administered intravenously Administered orally |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Progression-Free Survival (PFS) by Independent Review Committee (IRC)
時間枠:Approximately 36 Months
|
PFS is defined as time from the date of randomization to the date of first disease progression or death, whichever occurs first, as determined by IRC using modified 2018 International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria for participants with chronic lymphocytic leukemia (CLL) and Lugano classification for participants with small lymphocytic lymphoma (SLL). |
Approximately 36 Months
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Overall Survival (OS)
時間枠:Approximately 36 Months
|
OS is defined as time from the date of randomization to the date of death due to any cause. |
Approximately 36 Months
|
|
PFS by the Investigator Assessment
時間枠:Approximately 36 Months
|
PFS is defined as time from the date of randomization to the date of first disease progression or death, whichever occurs first, as determined by the investigator using modified 2018 iwCLL criteria for participants with CLL and Lugano classification for participants with SLL |
Approximately 36 Months
|
|
Rate of Partial Response with Lymphocytosis (PR-L) or Higher Determined by IRC and by Investigator Assessment
時間枠:Approximately 36 Months
|
Rate of PR-L or higher is defined as the percentage of participants with a best overall response of CR, CRi, nPR, PR, or PR-L as assessed by the IRC or by the Investigator |
Approximately 36 Months
|
|
Duration of Response (DOR) by IRC and Investigator Assessment
時間枠:Approximately 36 Months
|
DOR is defined as the time from initial response to disease progression or death, whichever occurs first, as assessed by the IRC or by the investigator. |
Approximately 36 Months
|
|
Time to Next Anti-CLL/SLL Treatment (TTNT)
時間枠:Approximately 36 Months
|
TTNT is defined as the time from the date of randomization to the date of next anti-CLL/SLL treatment. |
Approximately 36 Months
|
|
Change from baseline in EORTC Quality of Life Questionnaire - Chronic Lymphocytic Leukemia Module 17 Items (QLQ-CLL17) Symptom Burden and Physical Condition Scales
時間枠:Approximately 24 Months
|
The symptom burden and physical condition will be measured by QLQ-CLL17. EORTC QLQ-CLL17 comprises 17 items grouped into 3 multi-item scales: 1) symptom burden, 2) physical condition/fatigue, and 3) worries/fears about health and functioning. Each question is rated using a 4-point response scale ("not at all," "a little," "quite a bit," and "very much") and the recall period for all items is the past 7 days. The scores of each subscale are calculated based on the EORTC's protocol and then transformed to a 0 to 100 scale. Higher scores represent higher levels of symptom burden, physical condition/fatigue, or worries/fears about health and functioning. |
Approximately 24 Months
|
|
Progression-Free Survival (PFS) in Participants with Prior Exposure to Noncovalent Bruton Tyrosine Kinase Inhibitor(s) (ncBTKi) by IRC
時間枠:Approximately 36 Months
|
PFS is defined as time from the date of randomization to the date of first disease progression or death, whichever occurs first, as determined by IRC using modified 2018 iwCLL criteria for participants with chronic lymphocytic leukemia (CLL) and Lugano classification for participants with small lymphocytic lymphoma (SLL) for participants with prior exposure to ncBTKi. |
Approximately 36 Months
|
|
Overall Response Rate (ORR) by IRC and Investigator Assessment
時間枠:Approximately 36 Months
|
ORR is defined as the percentage of participants with best overall response of complete response (CR), complete response with incomplete bone marrow recovery (CRi), nodular partial remission (nPR), or partial response (PR) as assessed by the IRC or by the investigator. |
Approximately 36 Months
|
|
Number of Participants With Treatment-emergent Adverse Events (TEAEs), Treatment-emergent Serious Adverse Events (TESAEs), and Laboratory Abnormalities
時間枠:Approximately 36 Months
|
Safety will be assessed by monitoring and recording of all treatment emergent adverse events (AEs) graded by National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0. |
Approximately 36 Months
|
|
Change from Baseline in European Organization for Research and Treatment of Cancer Quality of Life Cancer Questionnaire-Core 30 (EORTC QLQ-C30) Global Health Status/QoL (GHS) Physical Functioning and Role Functioning Scales
時間枠:Approximately 24 Months
|
The EORTC QLQ-C30 contains 30 questions that incorporate 5 functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning), 1 global health status scale, 3 symptom scales(fatigue, nausea and vomiting, and pain), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The participant answers questions about their health during the past week. There are 28 questions answered on a 4-point scale where 1=Not at all (best) to 4=Very Much (worst) and 2 questions answered on a 7-point scale where 1=Very poor (worst) to 7=Excellent (best). Higher scores in GHS and functional scales indicate better quality of life. |
Approximately 24 Months
|
協力者と研究者
スポンサー
捜査官
- スタディディレクター:Study Director、BeOne Medicines
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
- 病理学的プロセス
- 新生物
- 慢性疾患
- 疾患の属性
- 免疫系疾患
- 組織型別の新生物
- 血液疾患
- リンパ疾患
- リンパ増殖性疾患
- 免疫増殖性疾患
- 白血病、B細胞
- 白血病、リンパ
- 白血病
- 病理学的状態、徴候および症状
- ヘミックおよびリンパ疾患
- 白血病、リンパ球、慢性、B細胞
- アミノ酸、ペプチド、およびタンパク質
- タンパク質
- 有機化学物質
- 複素環化化合物
- ベンジミダゾール
- 複素環化化合物、2リング
- 複素環化化合物、融合リング
- 炭化水素
- 酸、非環式
- カルボン酸
- 抗体、モノクローナル
- 抗体
- 免疫グロブリン
- 免疫タンパク質
- 血液タンパク質
- 血清グロブリン
- グロブリン
- 窒素マスタード化合物
- マスタード化合物
- 炭化水素、ハロゲン化
- 酪酸
- 抗体、モノクローナル、マウス由来
- ベンダムスチン塩酸塩
- リツキシマブ
- ベネトクラックス
- idelalisib
その他の研究ID番号
- BGB-16673-302
- 2024-518893-15-00 (Ctis)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
BeOne shares data on completed studies responsibly and provides qualified scientific and medical researchers access to data and supporting documentation for clinical trials in dossiers for medicines and indications after submission and approval in the United States, China, and Europe. Clinical trials supporting subsequent local approvals, new indications, or combination products are eligible for sharing once corresponding regulatory approvals are achieved.
BeOne shares data only when permitted by applicable data privacy and security laws and regulations, when it is feasible to do so without compromising the privacy of study participants, and other considerations.
Qualified researchers with appropriate competencies who are engaged in novel scientific research may submit a request for participant-level data with a research proposal for BeOne review. Research teams must include a biostatistician and sign a Data Sharing Agreement prior to receiving access to clinical trial data.
IPD 共有時間枠
See plan description
IPD 共有アクセス基準
See plan description
IPD 共有サポート情報タイプ
- STUDY_PROTOCOL
- SAP
- CSR
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。